Standard
Successful treatment of psoriasis with adalimumab induced no changes in the gut microbiota. / Todberg, T.; Egeberg, A.; Zachariae, C.; Sørensen, N.; Pedersen, O.; Skov, L.
I:
Journal of the European Academy of Dermatology and Venereology, Bind 36, Nr. 6, 2022, s. e464-e467.
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning
Harvard
Todberg, T
, Egeberg, A, Zachariae, C, Sørensen, N
, Pedersen, O & Skov, L 2022, '
Successful treatment of psoriasis with adalimumab induced no changes in the gut microbiota',
Journal of the European Academy of Dermatology and Venereology, bind 36, nr. 6, s. e464-e467.
https://doi.org/10.1111/jdv.17952APA
Todberg, T.
, Egeberg, A., Zachariae, C., Sørensen, N.
, Pedersen, O., & Skov, L. (2022).
Successful treatment of psoriasis with adalimumab induced no changes in the gut microbiota.
Journal of the European Academy of Dermatology and Venereology,
36(6), e464-e467.
https://doi.org/10.1111/jdv.17952Vancouver
Todberg T
, Egeberg A, Zachariae C, Sørensen N
, Pedersen O, Skov L.
Successful treatment of psoriasis with adalimumab induced no changes in the gut microbiota.
Journal of the European Academy of Dermatology and Venereology. 2022;36(6):e464-e467.
https://doi.org/10.1111/jdv.17952Author
Todberg, T. ; Egeberg, A. ; Zachariae, C. ; Sørensen, N. ; Pedersen, O. ; Skov, L. / Successful treatment of psoriasis with adalimumab induced no changes in the gut microbiota. I: Journal of the European Academy of Dermatology and Venereology. 2022 ; Bind 36, Nr. 6. s. e464-e467.
Bibtex
@article{24c70873932f470eb48bcc764d0c1f2a,
title = "Successful treatment of psoriasis with adalimumab induced no changes in the gut microbiota",
author = "T. Todberg and A. Egeberg and C. Zachariae and N. S{\o}rensen and O. Pedersen and L. Skov",
note = "Funding Information: This study was supported by Aage Bangs Foundation, Roberts Wehnerts and Kirsten Wehnerts Foundation, Liv Bryhns Foundation, Grosserer Fogts Foundation, The LEO Foundation and The Novo Nordisk Foundation Center for Basic Metabolic Research. Funding Information: TT has been an investigator for Novartis, Abbvie, Dr. Wolff, Galderma and Almirall. AE has received research funding from Pfizer, Eli Lilly, Novartis, Bristol‐Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Gal{\'a}pagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol‐Myers Squibb and Janssen Pharmaceuticals. CZ has been an advisor, investigator and speaker for Abbvie, Eli Lilly, Novatis, Sanofi, Leo pharma, UCB, CSL and Almirall. LS has been an advisor, investigator and speaker for Abbvie, Eli Lilly, Novartis, Sanofi, Celegene, Leo pharma, BMS, UCB and BI outside the submitted work. LS reports non‐financial support from Abbvie, Sanofi, Janssen and grants from Novartis, Janssen, BMS and Sanofi. The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent research centre at the University of Copenhagen that is partially funded by an unrestricted donation from the Novo Nordisk Foundation. The funding sources had no role in the study design, data collection, data analysis, data interpretation or writing of the manuscript. ",
year = "2022",
doi = "10.1111/jdv.17952",
language = "English",
volume = "36",
pages = "e464--e467",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "Elsevier",
number = "6",
}
RIS
TY - JOUR
T1 - Successful treatment of psoriasis with adalimumab induced no changes in the gut microbiota
AU - Todberg, T.
AU - Egeberg, A.
AU - Zachariae, C.
AU - Sørensen, N.
AU - Pedersen, O.
AU - Skov, L.
N1 - Funding Information:
This study was supported by Aage Bangs Foundation, Roberts Wehnerts and Kirsten Wehnerts Foundation, Liv Bryhns Foundation, Grosserer Fogts Foundation, The LEO Foundation and The Novo Nordisk Foundation Center for Basic Metabolic Research.
Funding Information:
TT has been an investigator for Novartis, Abbvie, Dr. Wolff, Galderma and Almirall. AE has received research funding from Pfizer, Eli Lilly, Novartis, Bristol‐Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol‐Myers Squibb and Janssen Pharmaceuticals. CZ has been an advisor, investigator and speaker for Abbvie, Eli Lilly, Novatis, Sanofi, Leo pharma, UCB, CSL and Almirall. LS has been an advisor, investigator and speaker for Abbvie, Eli Lilly, Novartis, Sanofi, Celegene, Leo pharma, BMS, UCB and BI outside the submitted work. LS reports non‐financial support from Abbvie, Sanofi, Janssen and grants from Novartis, Janssen, BMS and Sanofi. The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent research centre at the University of Copenhagen that is partially funded by an unrestricted donation from the Novo Nordisk Foundation. The funding sources had no role in the study design, data collection, data analysis, data interpretation or writing of the manuscript.
PY - 2022
Y1 - 2022
U2 - 10.1111/jdv.17952
DO - 10.1111/jdv.17952
M3 - Comment/debate
C2 - 35073450
AN - SCOPUS:85124560885
VL - 36
SP - e464-e467
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
SN - 0926-9959
IS - 6
ER -
